COLUMBUS, OHIO April 6, 2021 – Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller, […]
PRESS: Forge Biologics to Present at 2021 Virtual Cell and Gene Meeting on the Mediterranean

COLUMBUS, OHIO April 6, 2021 – Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller, […]
We are excited to unveil our Hearthside Chat series – our version of a fireside chat – from our home […]
The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients […]
We’re pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing […]
We are passionate about serving our clients by providing the highest quality vector and leading the industry in technological advancements. […]
We are thrilled to have a spotlight in National Venture Capital Association‘s (NVCA) Building Better blog series alongside Molly (McCartin) Bonakdarpour of Drive […]
With new beginnings comes new hope. As we enter 2021, screening will begin for the our Phase 1/2 RESKUE trial […]
As we begin 2021, we’d like to introduce you to our new Blaze Vector™ AAV production line. Utilizing our proprietary […]
Forge Biologics has received IND, IBC, and IRB clearance for FBX-101, a gene therapy for patients with Krabbe disease, a […]
In the spirit of football season, we’re introducing our very own roster of seasoned #genetherapy players. Our leadership team has […]